Bayer Reports Positive Phase III Results for NUBEQA® in Prostate Cancer Patients

Bayer presented positive Phase III results for NUBEQA® (darolutamide) at the ESMO 2026 congress, demonstrating a 58% reduction in the risk of metastasis or death in high-risk localized prostate cancer patients when combined with ADT and radiation therapy. This outcome marks a significant advancement in Bayer's oncology portfolio, particularly for its prostate cancer treatment strategy. The data was reported on October 24, 2026.